March 2015 March 2015
New Product - Femoston Conti
Femoston Conti (oestradiol and dydrogesterone) hormone replacement therapy is indicated in oestrogen deficiency associated with natural or artificial menopause in women with intact uteri; prevention of postmenopausal bone mineral density loss in women at high risk of osteoporosis and future fracture where nonoestrogen products are contraindicated or not tolerated. It is contraindicated in the following situations: hysterectomy; untreated endometrial hyperplasia; oestrogen dependent neoplasia (e.g. breast, endometrium), progestogen dependent neoplasm (including suspected); active, chronic or history of liver disease if liver function tests are still abnormal; cerebrovascular accident or history associated with oestrogen use; VTE; idiopathic VTE history; thrombophilic disorder including protein C, S or antithrombin deficiency; active, recent arterial thromboembolic disease, e.g. angina, myocardial infarction; undiagnosed abnormal genitourinary bleeding; porphyria; pregnancy (including suspected) and lactation. Femoston Conti (oestradiol 1 mg and dydrogesterone 5 mg) is available as a blister pack containing 28 tablets.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au